These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28421555)

  • 1. Pharmacological Agents Affecting Emesis : A Review (Part II).
    Mitchelson F
    Drugs; 1992 Apr; 43(4):443-463. PubMed ID: 28421555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological agents affecting emesis. A review (Part II).
    Mitchelson F
    Drugs; 1992 Apr; 43(4):443-63. PubMed ID: 1377113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological agents affecting emesis. A review (Part I).
    Mitchelson F
    Drugs; 1992 Mar; 43(3):295-315. PubMed ID: 1374316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonidine-induced emesis: a multitransmitter pathway concept.
    Japundzić-Zigon N; Samardzić R; Beleslin DB
    Pharmacol Res; 1997 Apr; 35(4):287-97. PubMed ID: 9264044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.
    Gylys JA; Wright RN; Nicolosi WD; Buyniski JP; Crenshaw RR
    J Pharmacol Exp Ther; 1988 Mar; 244(3):830-7. PubMed ID: 2978041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
    Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
    Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropharmacology of motion sickness and emesis. A review.
    Takeda N; Morita M; Hasegawa S; Horii A; Kubo T; Matsunaga T
    Acta Otolaryngol Suppl; 1993; 501():10-5. PubMed ID: 8447218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action.
    Freeman AJ; Cunningham KT; Tyers MB
    Anticancer Drugs; 1992 Apr; 3(2):79-85. PubMed ID: 1525396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
    Aapro M; Johnson J
    Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
    Jeremić B
    Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
    Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
    Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropharmacology of emesis in relation to clinical response.
    Costall B; Naylor RJ
    Br J Cancer Suppl; 1992 Dec; 19():S2-7; discussion S7-8. PubMed ID: 1467196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.
    Blower PR
    Eur J Cancer; 1990; 26 Suppl 1():S8-11. PubMed ID: 2169786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
    Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
    J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.